Patents by Inventor Olivier Hermine

Olivier Hermine has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210308106
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of systemic mastocytosis. The inventors showed the effect of KPT-251 treatment on SCF-dependent human Mast cell (MC) line without KIT mutation (WT ROSA) and on two factor-independent MC lines with KIT mutations: ROSA ? 417-419 insY and ROSA D816V. KPT is a Selective Inhibitor of Nuclear Export (SINE) that specifically inhibits the activity of the exportin-1 (XPO1). KPT-251 treatment induces minimal toxicity in non-cancerous hematopoietic cells both in vitro and in vivo. In particular, the present invention relates a method of treating systemic mastocytosis in patient in need thereof comprising administering to the patient a therapeutically effective amount of a XPO1 inhibitor.
    Type: Application
    Filed: May 19, 2021
    Publication date: October 7, 2021
    Inventors: Olivier HERMINE, Flavia GUILLEM, Gandhi DAMAJ, Sophia LADRAA
  • Patent number: 11065230
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of systemic mastocytosis. The inventors showed the effect of KPT-251 treatment on SCF-dependent human Mast cell (MC) line without KIT mutation (WT ROSA) and on two factor-independent MC lines with KIT mutations : ROSA ? 417-419 insY and ROSA D816V. KPT is a Selective Inhibitor of Nuclear Export (SINE) that specifically inhibits the activity of the exportin-1 (XPO1). KPT-251 treatment induces minimal toxicity in non-cancerous hematopoietic cells both in vitro and in vivo. In particular, the present invention relates a method of treating systemic mastocytosis in patient in need thereof comprising administering to the patient a therapeutically effective amount of a XPO1 inhibitor.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: July 20, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), FONDATION IMAGINE, UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS (APHP), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE DE CAEN NORMANDIE, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE CAEN
    Inventors: Olivier Hermine, Flavia Guillem, Gandhi Damaj, Sophia Ladraa
  • Patent number: 10647752
    Abstract: The present invention relates to agents capable of inhibiting the binding between Leptin and Neuropilin-1 (NRP1) and uses thereof in the therapeutic field.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: May 12, 2020
    Assignees: INSERM (Institut National de la Santé et de la Recherche Medicale), Fondation Imagine, Assistance Publique-Hopitaux de Paris (APHP), Université Paris Descartes, Centre National de la Recherche Scientifique (CNRS), Université de Bourgogne, CNAM—Conservatoire National des Arts at Metier
    Inventors: Zakia Belaid-Choucair, Olivier Hermine, Matthieu Montes, Carmen Garrido-Fleury, Renaud Seigneuric, Guillaume Marcion
  • Patent number: 10617658
    Abstract: The present invention relates to the use of hydroxycarbamide (HC) for reducing and/or delaying the extension of capillary nonperfusion, a cause of irreparable visual impairment in patients suffering from central retinal vein occlusion (CRVO). This is the first systemic treatment which makes it possible to reduce retinal ischemic complications in patients in whom (CRVO) has been recently diagnosed and is consequently in a rapidly progressive phase. Given the low toxicity of HC evaluated on a large scale in children and adults in the context of other diseases for decades, the results of the present study open up a new therapeutic approach in the treatment of CRVO.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: April 14, 2020
    Assignees: CENTRE HOSPITALIER NATIONAL D'OPHTALMOLOGIE QUINZE-VINGTS, INSTITUT NATIONAL DE LA SANTE DE LA RECHERCHE MEDICAL (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), IMAGINE INSTITUT DES MALADIES GENETIQUES NECKER ENFANTS MALADES, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, UNIVERSITE PARIS DESCARTES
    Inventors: Yves Colin, Jean-Francois Girmens, Olivier Hermine, Emmanuel Heron, Michel Paques
  • Publication number: 20200108053
    Abstract: The inventors demonstrate for the first time the activation of the Hedgehog (HH) signaling pathway in normal and abnormal human mast cells (MCs). These results prompt the inventors to explore the consequence of the inhibition of the HH pathway, especially the canonical pathway, on MC proliferation. They demonstrate that Hedgehog inhibitors inhibit proliferation and induces apoptosis of mast cells. Accordingly the present invention relates to a method of treating a mast cell disease in a patient in need there of comprising administering to the patient a therapeutically effective amount of a Hedgehog inhibitor.
    Type: Application
    Filed: May 17, 2018
    Publication date: April 9, 2020
    Inventors: Leila MAOUCHE-CHRETIEN, Christine BODEMER, Olivier HERMINE, Laura POLIVKA
  • Publication number: 20190247416
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of systemic mastocytosis. The inventors showed the effect of KPT-251 treatment on SCF-dependent human Mast cell (MC) line without KIT mutation (WT ROSA) and on two factor-independent MC lines with KIT mutations : ROSA ? 417-419 insY and ROSA D816V. KPT is a Selective Inhibitor of Nuclear Export (SINE) that specifically inhibits the activity of the exportin-1 (XPO1). KPT-251 treatment induces minimal toxicity in non-cancerous hematopoietic cells both in vitro and in vivo. In particular, the present invention relates a method of treating systemic mastocytosis in patient in need thereof comprising administering to the patient a therapeutically effective amount of a XPO1 inhibitor.
    Type: Application
    Filed: September 15, 2017
    Publication date: August 15, 2019
    Inventors: Olivier HERMINE, Flavia GUILLEM, Gandhi DAMAJ, Sophia LADRAA
  • Publication number: 20190049469
    Abstract: Provided herein are methods of treating diseases associated with anemia or ineffective erythropoiesis by using the level and/or activity of a ligand of an activin receptor, in particular, Growth differentiation factor 11 (GDF11), as an indicator of responsiveness of a patient to the treatment, efficacy of the treatment, or appropriate dosage for the treatment with an activin type II receptor inhibitor.
    Type: Application
    Filed: March 9, 2018
    Publication date: February 14, 2019
    Applicant: CELGENE CORPORATION
    Inventors: Victoria Sung, Rajesh Chopra, Olivier Hermine, Ivan Cruz Moura, Michael Dussiot, Thiago Trovati Maciel, Aurelie Fricot
  • Publication number: 20190002569
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and infectious diseases in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of the NRP-1/OBR signaling pathway.
    Type: Application
    Filed: September 4, 2018
    Publication date: January 3, 2019
    Inventors: Zakia Belaid-Choucair, Olivier Hermine, Carmen Garrido-Fleury, Claude Cochet, Odile Filhol-Cochet, Renaud Seigneuric
  • Patent number: 10151745
    Abstract: The present invention relates to a method for determining whether a candidate human transplant donor is at risk of inducing acute graft versus host disease (aGVHD) in a human transplant recipient, which may in turn allow the selection of a donor exhibiting no risk for the recipient. The present invention also relates to a method for adjusting the immunosuppressive treatment administered to a human transplanted recipient following its graft transplantation after having performing the method for determining risk of the invention. The methods comprise expanding the candidate donor's iNKT cells (invariant NKT cells) and determining the presence or absence of expansion of the CD4(?) iNKT cell sub-population. In particular, CD3+CD4? TCRV[alpha]24V[beta]11 cells are determined. Kits are disclosed.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: December 11, 2018
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Assistance Publique—Hopitaux de Paris, Universite Paris Descartes, Imagine Institut des Maladies Genetiques Necker Enfants Malades
    Inventors: Olivier Hermine, Marie Thérèse Rubio, Marie Bouillie, Maria Leite de Maraes
  • Patent number: 10111896
    Abstract: The present invention concerns a combination of (i) a DNA methylation inhibitor, and (ii) a Vitamin D receptor agonist, for simultaneous or sequential use in the treatment of a drug resistant cancer and/or in prevention of tumor relapse in a patient suffering from cancer. The present invention also relates to a combination of (i) a DNA methylation inhibitor, and (ii) a Vitamin D receptor agonist, for increasing, restoring or enhancing sensitivity of a patient suffering from cancer to a chemotherapeutic drug in a patient suffering from cancer.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: October 30, 2018
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (C.N.R.S.), Universite Paris Descartes, Foundation Imagine, Universite Paris Diderot—Paris 7, Universite Paris—Sud, Assistance Publique-Hopitaux de Paris (APHP)
    Inventors: Ivan Cruz-Moura, Olivier Hermine, Etienne Paubelle, Michael Dussiot, Thiago Trovati Maciel, Florence Zylbersztejn
  • Publication number: 20180230189
    Abstract: The present invention relates to agents capable of inhibiting the binding between Leptin and Neuropilin-1 (NRP1) and uses thereof in the therapeutic field.
    Type: Application
    Filed: September 21, 2016
    Publication date: August 16, 2018
    Inventors: Zakia Belaid-Choucair, Olivier Hermine, Matthieu Montes, Carmen Garrido-Fleury, Renaud Seigneuric, Guillaume Marcion
  • Publication number: 20180221313
    Abstract: The present invention relates to the use of hydroxycarbamide (HC) for reducing and/or delaying the extension of capillary nonperfusion, a cause of irreparable visual impairment in patients suffering from central retinal vein occlusion (CRVO). This is the first systemic treatment which makes it possible to reduce retinal ischemic complications in patients in whom (CRVO) has been recently diagnosed and is consequently in a rapidly progressive phase. Given the low toxicity of HC evaluated on a large scale in children and adults in the context of other diseases for decades, the results of the present study open up a new therapeutic approach in the treatment of CRVO.
    Type: Application
    Filed: August 8, 2016
    Publication date: August 9, 2018
    Applicant: Centre National De La Recherche Scientifique (CNRS)
    Inventors: Yves COLIN, Jean-Francois GIRMENS, Olivier HERMINE, Emmanuel HERON, Michel PAQUES
  • Publication number: 20180031579
    Abstract: The present invention relates to antagonists of GDF11, for use in the treatment of malignant hematological disease, such as Acute Myeloid Leukemia (AML). The present invention also relates to a method for predicting the responsiveness of a patient affected with malignant haematological disease, such as Acute Myeloid Leukemia, to a chemotherapy treatment.
    Type: Application
    Filed: February 11, 2016
    Publication date: February 1, 2018
    Inventors: Ivan CRUZ-MOURA, Valérie BARDET, Michaël DUSSIOT, Thiago TROVATI MACIEL, Jérôme TAMBURINI, Norbert IFRAH, Olivier HERMINE
  • Patent number: 9861615
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of beta-thalassemias. In particular, the present invention relates to an XPO1 inhibitor for use in a method for treating beta-thalassemia in a subject in need thereof.
    Type: Grant
    Filed: November 28, 2014
    Date of Patent: January 9, 2018
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite Paris Decartes, Assistance Publique-Hopitaux de Paris (APHP), Fondation Imagine, Centre National de la Recherche Scientifique (CNRS)
    Inventors: Olivier Hermine, Flavia Guillem, Jean-Benoit Arlet, Genevieve Courtois
  • Patent number: 9675590
    Abstract: The present invention provides methods and pharmaceutical compositions designed to intervene in this defective process and to promote or restore erythrocyte maturation in individuals suffering from a myelodysplastic syndrome. The methods involve maintaining the activity of GATA-1 by preventing sequestration of Hsp70 in the cytoplasm. Accordingly, it is an object of this invention to provide methods of restoring or increasing erythrocyte maturation in a subject suffering from a myelodysplastic syndrome by preventing proteolytic inactivation of GATA-1. In some embodiments, preventing is achieved by administering to the subject a compound that inhibits the XPO1 nuclear transporter.
    Type: Grant
    Filed: June 9, 2015
    Date of Patent: June 13, 2017
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Fondation Imagine, Assistance Publique-Hopitaux de Paris (APHP), Universite Paris Descartes, Centre National de la Recherche Scientifique (CNRS)
    Inventors: Olivier Hermine, Flavia Guillem, Jean-Benoit Arlet, Genevève Courtois, Michaela Fontenay
  • Publication number: 20170119804
    Abstract: The present invention concerns a combination of (i) a DNA methylation inhibitor, and (ii) a Vitamin D receptor agonist, for simultaneous or sequential use in the treatment of a drug resistant cancer and/or in prevention of tumor relapse in a patient suffering from cancer. The present invention also relates to a combination of (i) a DNA methylation inhibitor, and (ii) a Vitamin D receptor agonist, for increasing, restoring or enhancing sensitivity of a patient suffering from cancer to a chemotherapeutic drug in a patient suffering from cancer.
    Type: Application
    Filed: June 19, 2015
    Publication date: May 4, 2017
    Inventors: Ivan Cruz-Moura, Olivier Hermine, Etienne Paubelle, Michael Dussiot, Thiago Trovati Maciel, Florence Zylbersztejn
  • Publication number: 20170100378
    Abstract: The present invention provides methods and pharmaceutical compositions designed to intervene in this defective process and to promote or restore erythrocyte maturation in individuals suffering from a myelodysplastic syndrome. The methods involve maintaining the activity of GATA-1 by preventing sequestration of Hsp70 in the cytoplasm. Accordingly, it is an object of this invention to provide methods of restoring or increasing erythrocyte maturation in a subject suffering from a myelodysplastic syndrome by preventing proteolytic inactivation of GATA-1. In some embodiments, preventing is achieved by administering to the subject a compound that inhibits the XPO1 nuclear transporter.
    Type: Application
    Filed: June 9, 2015
    Publication date: April 13, 2017
    Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DA LA RECHERCHE MÉDICALE)
    Inventor: Olivier HERMINE
  • Publication number: 20170051062
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and infectious diseases in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of the NRP-1/OBR signaling pathway.
    Type: Application
    Filed: February 18, 2015
    Publication date: February 23, 2017
    Inventors: Zakia Belaid-Choucair, Olivier Hermine, Carmen Garrido-Fleury, Claude Cochet, Odile Filhol-Cochet, Renaud Seigneuric
  • Publication number: 20170020847
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of beta-thalassemias. In particular, the present invention relates to an XPO1 inhibitor for use in a method for treating beta-thalassemia in a subject in need thereof.
    Type: Application
    Filed: November 18, 2014
    Publication date: January 26, 2017
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP), FOUNDATION IMAGINE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Olivier HERMINE, Flavia GUILLEM, Jean-Benoit ARLET, Genevieve COURTOIS
  • Publication number: 20160368975
    Abstract: Methods and compositions for the treatment of ?-thalassemia are provided. Methods and compositions restore or increase erythrocyte maturation in individuals afflicted with ?-TM by preventing proteolysis of GATA-1 protein. Screening methods for identifying agents which bind heat shock protein 70 (HSP-70) and inhibit HSP-70 ?-globin binding, but which allow GATA-1 protein-HSP-1 binding in a manner that prevents GATA-1 proteolysis.
    Type: Application
    Filed: May 23, 2016
    Publication date: December 22, 2016
    Inventors: Olivier HERMINE, Genevieve COURTOIS, Jean-Benoit ARLET, Jean-Antoine RIBEIL